**N. Ireland Cancer Registry**

**Implications of Research for Services**

|  |  |
| --- | --- |
|  | NICR Lead Author  *(Office use only)* |
|  | Paper ID      *(Office use only)* |
|  | Date Submitted to NICR Steering Group Click here to enter a date.*(Office use only)* |
| **Paper Title** | Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study |
| **Authors** | Amy Downing, Penny Wright, Luke Hounsome, Peter Selby, Sarah Wilding, Eila Watson, Richard Wagland, Paul Kind, David W Donnelly, Hugh Butcher, James W F Catto, William Cross, Malcolm Mason, Linda Sharp, David Weller, Galina Velikova, Eilis McCaughan, Rebecca Mottram, Majorie Allen, Therese Kearney, Oonagh McSorley, Dyfed W Huws, David H Brewster, Emma McNair, Anna Gavin\*, Adam W Glaser\* |
| **Journal** | Lancet oncology  |
| **DOI** | doi.org/10.1016/S1470-2045(18)30780-0  |
| **Funders** | Movember Foundation in partnership with Prostate Cancer UK |
| **Full paper available online** | YES [x]  NO [ ]  NOT YET [ ]  |
| **Conclusion** | Men diagnosed with advanced disease do not report substantially different Health Related Quality Of Life outcomes to those diagnosed with localised disease, although considerable problems with hormonal function and fatigue are reported in men treated with androgen deprivation therapy. Sexual dysfunction is common and most men are not offered helpful intervention or support. Service improvements around sexual rehabilitation and measures to reduce the effects of androgen deprivation therapy are required. |
| **What this means for the service** | 1/3 men diagnosed with Prostate Cancer are asymptomatic PSA detected. This has resulted in significant increases in numbers of patients living with a diagnosis of Prostate Cancer. Many report problems with Urinary incontinence (13%) Bowel problems (8%) Poor erections (81%) 94% post surgery. These represent significant problems for men and the service as it copes with increased numbers of men living after a diagnosis of prostate cancer (see table 3 below)   |